SCHEDULE 13G/A 0000929638-24-000649 0001599214 XXXXXXXX LIVE 2 Class A Ordinary Shares 09/30/2025 0001821586 MoonLake Immunotherapeutics 61559X104 Dorfstrasse 29 Zug V8 6300 Rule 13d-1(b) Chen Bihua b X1 0 1994173 0 1994173 1994173 N 3.14 IN HC MoonLake Immunotherapeutics Dorfstrasse 29, Zug, Switzerland, 6300 Bihua Chen This statement is filed by Bihua Chen, with respect to the shares held for the benefit of investment funds for which Cormorant Asset Management, LP serves as the investment manager. Bihua Chen serves as the general partner of Cormorant Asset Management, LP. The foregoing person is hereinafter referred to as the "Reporting Person." The filing of this statement should not be construed as an admission that the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein. 200 Clarendon Street, 52nd Floor Boston, MA 02116 United States N HC 1,994,173 3.14% 0 1,994,173 0 1,994,173 The percentages reported herein with respect to the Reporting Person's holdings are calculated based upon a statement in the Issuer's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as filed with the Securities and Exchange Commission on August 5, 2025, that there were 63,501,402 Class A Ordinary Shares of the Issuer outstanding as of August 1, 2025. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Chen Bihua /s/ Bihua Chen 10/01/2025